The AHA responds to the Health Resources and Services Administration’s (HRSA) Request for Information regarding a potential 340B Rebate Model Pilot Program.
AbbVie is spearheading a new battle in pharma’s long-running fight to reform the federal government’s 340B drug discount program with a lawsuit that challenges the definition of what it means to be a ...
LYNN– At a recent State House briefing hosted by the Massachusetts Health & Hospital Association, healthcare leaders gathered ...
Senate Bill 5981, signed into law by Gov. Bob Ferguson on March 25, strengthened the federal 340B Drug Pricing Program, ...
A federal court has struck down a 12-year-old Health Resources and Services Administration policy that restricted how certain 340B hospitals could make initial drug purchases, finding that the agency ...
The AHA and others April 17 filed an amicus brief requesting the U.S. Court of Appeals for the 4th Circuit grant en banc ...
Craig Bleifer, Michael Podberesky, Jessica Vaughn, Ph.D. The 340B Program requires participating drug manufacturers to sign a pharmaceutical pricing agreement (“PPA”) with the Secretary of Health and ...
Hospitals and clinics told regulators that switching to rebates in the 340B drug discount program would impose costs that ...
The 340B Drug Pricing Program must be reformed to better patient health and disincentivize institutional profit-seeking ...
In February 2026, the Department of Justice filed amicus briefs supporting pharmaceutical manufacturers, asserting that Rhode ...
Hospital and pharma groups have sharpened their spears for the rematch on 340B rebates. | The administration's second stab ...
AHA urges HRSA to axe 340B model that would cost hospitals over $1 billion annually and increase administrative burdens.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results